Tag Archives: Immunotherapy

Highlighting a DNA-Based Lymphoma Treatment

Highlighting a DNA-Based Lymphoma Treatment
Highlighting a DNA-Based Lymphoma Treatment

One of the benefits of cancer immunotherapy is that it can offer options for patients when other treatments have failed. Doctors are having success with a new DNA-based treatment for certain forms of lymphoma.

CAR T-cell Therapy and Lymphoma

Chimeric antigen receptor T-cell therapy (or CAR T-cell therapy) may sound complicated, but the basic principle is simple. CAR T-cell therapy, like most types of cancer immunotherapy, works by boosting the ability of a patient’s own immune system to fight cancer.

With this procedure, T-cells are harvested from a patient and genetically engineered to produce surface receptors. The T-cells are then reintroduced into the patient’s system, where the receptors target a specific protein expressed by the lymphoma cells.

Dimas Padilla, a 44-year-old man from Orlando whose lymphoma had returned for a third time, was one of the 101 patients involved in a test of CAR T-cell therapy. Approximately half of the group experienced complete remission. Padilla himself has been tumor-free for 18 months.

Yescarta Wins FDA Approval

In October 2017, the FDA approved this treatment under the trade name Yescarta for use with certain types of B-cell lymphoma. This is only the second gene therapy to pass FDA approval, but at this point usage is restricted to patients who have unsuccessfully undergone at least two other forms of treatment.

Issels®: Personally Developed Cancer Immunotherapy for All Patients

No two cases of cancer are the same. Our non-toxic immunotherapy programs are created to meet each patient’s needs, even if previous treatments have failed. Contact us to learn how we have helped numerous patients achieve long-term remission.

“Superblood” Engineered to Carry Cancer Fighting Proteins

"Superblood" Engineered to Carry Cancer Fighting Proteins
“Superblood” Engineered to Carry Cancer Fighting Proteins

Super powers are usually the stuff of comic books and movies, but a biotech startup may be turning fiction into reality with the development of “superblood” as a revolutionary new cancer treatment.

“Supercharging” Red Blood Cells

Rubius Therapeutics is working on a program called Red-Cell Therapeutics (RCT), which involves red blood cells that are genetically engineered to fight cancer. Once introduced into a patient’s system, these proteins can replace missing enzymes and help the immune system attack and destroy cancer cells.

RCT has two major advantages that make it a promising breakthrough in cancer treatment:

– The nuclei have been removed from these cells so they can’t be recognized by the immune system, leaving them free from interference so they can do their job.

– Red blood cells travel throughout the entire body, so RCT is able to easily reach any affected organs or tissues.

Thanks to these two features, RCT has the potential to treat patients without the need for an individually developed solution.

What’s Next?

Initially, Rubius Therapeutics generated $120 million from investors. The company recently raised an additional $100 million for a total of nearly a quarter of a billion dollars in less than one year. According to Rubius president Torben Straight Nissen, this funding will help accelerate RCT development for quicker delivery to the end users.

Issels®: The Leader in Immunotherapy Cancer Treatments

Much like RCT, cancer treatment at Issels® is designed to boost the immune system’s ability to attack and kill cancer cells. Contact us to learn more about cancer vaccines and other programs we have used to help patients achieve long-term remission.

Seed Money from Give Hope Will Help to Fund Pancreatic Cancer Research

New Cancer Research Is Improving Treatment
New Cancer Research Is Improving Treatment

Nearly everyone in America has been touched by cancer, whether it’s through personal experience or that of a friend or family member. One woman literally turned her loss into hope for continued research in immunotherapy for cancer and other treatments.

Sorrow Gives Rise to Hope

Susan Hunt’s experience came when her best friend Beth was diagnosed with pancreatic cancer. Hunt mourned the time they lost together, but she challenged her grief into Give Hope, the all-volunteer group she founded to raise seed money for continued research into new treatments and possible cures.

When it comes to cancer research, scientists are faced with a catch-22: they need data to present to the big cancer foundations in order to secure research grants, but they require money to generate the data in the first place. Give Hope has provided major funding for pancreatic cancer studies at the University of Cincinnati.

“Bench to Bedside”

Dr. Syed Ahmad of UC’s Cancer Institute used the term “bench to bedside” to sum up the research process. Every idea begins on a laboratory bench, where it’s nurtured with time and resources until it ends up at a patient’s bedside.

According to Hunt, the seed money raised by Give Hope has generated nearly $2 million in pancreatic cancer research funding for UC. University officials explained that after three years, the Cancer Institute receives $35 for every one dollar in seed money.

Immunotherapy for Cancer: The Issels® Difference

Our individually developed cancer treatment programs are not clinical trials. We have had years of success treating patients of all ages with all types of cancer. Contact us for more information.

Using Viruses to Boost the Immune Response in Immunotherapy

Medical Research Has Validated that Immunotherapy Works to Fight Cancer
Medical Research Has Validated that Immunotherapy Works to Fight Cancer

When it comes to your health, viruses are usually thought of as something to avoid. New studies have shown that infecting tumors with viruses can actually boost the beneficial effects of immunotherapy for cancer.

Helping the Immune System Target Tumors

Your body’s immune system is the primary line of defense against invading cells. One of the barriers to successful cancer treatment has been the ability of cancer cells to evade detection, leaving them free to grow unchecked.

On the other hand, the immune system has an excellent ability to recognize viruses. Two separate studies show evidence that cancer-targeting viruses might be able to trigger an immune attack on tumors.

– A team in England injected nine brain tumor patients with a cancer-seeking virus. After the tumors were surgically removed, researchers discovered that the viruses had indeed reached their target, and there were signs that the viral infection caused an immune response.

– Researchers in Canada performed similar tests on mice with breast cancer. The virus was injected directly into the tumors, and while it had little effect on survival rates, the infected mice had fewer instances of tumors spreading.

Viruses and Immunotherapy for Cancer

Professor John Bell, senior author of the latter study, explained that the virus “raises a big red flag” to alert the immune system. He went on to say that the addition of a checkpoint inhibitor enables a full-force immune attack.

State-of-the-Art Immunotherapy Treatments at Issels®

The non-toxic, individually developed immunotherapy for cancer treatments at Issels® are directed at enhancing the power of your own immune system. Contact us to learn more about our integrative programs.

Properties of Breast Tissue May Play a Role in Cancer Progression

There is New Hope for Breast Cancer Treatment
There is New Hope for Breast Cancer Treatment

Doctors have found some success with immunotherapy for cancer during the late stages of the disease, but the mystery of what causes certain tumors to spread has remained unsolved. Scientists are now turning to a surprising source for information about breast cancer progression.

A Matter of Engineering?

Ovijit Chaudhuri, an assistant professor of mechanical engineering, has been working with researchers across campus exploring the mechanical properties of breast tissue and their role in cancer progression. According to Chaudhuri, evidence supporting this relationship has been accumulating over the last 20 years.

Questions being studied by the teams include:

– How does stiffness of breast tissue encourage the growth and spread of tumors? Chaudhuri’s group is culturing mammary cells inside a hydrogel and tuning its stiffness to determine how it affects the development of cancer cells.

– How do cancer cells find their way past the membrane surrounding breast tissue that is seemingly too dense to allow passage? Currently, the scientists theorize that the cells use a combination of enzymes and force to “cut” their way through.

– As surrounding tissue grows in stiffness over time, how do tumors find space to expand?

Mechanobiology: A Complementary Approach

This isn’t the first time that scientists have sought biological information from the field of engineering. The result is the hybrid science of mechanobiology, which studies the interactions of mechanical properties and biological processes.

Immunotherapy for Cancer: Treating Resistant Tumors

At Issels®, our non-toxic immunotherapy programs have helped patients with advanced and therapy-resistant cancers achieve long-term remission. Visit our website for more information about our successful history of personally tailored and integrative cancer treatment programs.

One Important Step to Improving Treatment for Therapy-Resistant Cancers

Cancer Therapies at the Molecular Level in Intracellular Proteins
Cancer Therapies at the Molecular Level in Experimental Antibodies

The use of immunotherapy for cancer has helped many patients with cancers that are difficult to treat or cancers that have spread. However, there have been certain limits on how this treatment works. In some cases, tumors have become resistant to this form of treatment. Researchers have been working on a combination therapeutic approach that shows more promise in effectively fighting cancer.

Experimental Antibody

Researchers at Stanford and Yale developed an experimental antibody that is able to target more immune cells that are involved with the growth of tumors. Current immunotherapy approaches focus on a smaller number of these immune cells, which limits their ability to eliminate cancerous tumors. While these approaches have stopped cancer from spreading in some cases, they have been unable to successfully deal with tumor growth in other cases.

The experimental antibody is able to prevent another type of immune cell, known as a myeloid cell, from contributing to tumor growth and immunotherapy drug resistance.

Combination Immunotherapy

The use of this experimental antibody along with immunotherapy drugs is showing the potential for effectively fighting cancer. Researchers have used it on cell culture models and mouse models that contain human cell membrane proteins. This combination immunotherapy approach limits the growth of tumor cells, making it harder for them to thrive and spread. Researchers still need to do more studies on this experimental antibody in order to determine if it can be used to treat cancer cases that are metastatic or more advanced.

To learn more about immunotherapy for cancer, please visit Issels®. We offer advanced programs for those who are looking for nontoxic forms of cancer treatment.